Exercise effectively eases fatigue and improves muscular fitness in MS patients, but the best type differs for each outcome, ...

Columnist Ben Hofmeister recognizes how he doesn't want to lose control, even as he's learning to part with it willingly.

Immutep said IMP761 was found safe in initial data from a Phase 1 trial, with no treatment-related adverse events reported.

Columnist Desiree Lama has been living with MS for several years, yet she still appreciatea the advice and advocacy of her ...

About four in five adults with long-term stable MS who stopped first-line treatment with a DMT showed signs of disease ...

Columnist Ahna Crum knows what MS has taken from her, but she also recognizes the significant gifts it's granted over the ...

Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...